PUBLISHER: Grand View Research | PRODUCT CODE: 1869760
PUBLISHER: Grand View Research | PRODUCT CODE: 1869760
U.S. Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti-inflammatory, Bronchodilators), By Device Type (Inhalers, Nebulizers), By Route of Administration (Oral, Inhaled), By Product, And Segment Forecasts, 2025 - 2033
Market Size & Trends:
The U.S. asthma therapeutics market size was estimated at USD 13.00 billion in 2024 and is projected to reach USD 19.20 billion by 2033, growing at a CAGR of 4.5% from 2025 to 2033. The rising number of asthma patients in the U.S. has led to a growing demand for effective therapies, including some of the most advanced and promising treatment options.
The U.S. asthma therapeutics market is experiencing steady growth, driven by a rising number of asthma cases. According to the American Lung Association, over 25 million people in the U.S. are living with asthma, and approximately 5-10% of them have severe asthma, highlighting the urgent need for more effective and targeted treatment options.Although various therapies are available, many patients continue to experience frequent asthma attacks, highlighting the limitations of current medications. In response, pharmaceutical companies invest in developing advanced therapies that offer targeted and more effective solutions.
In February 2023, Amgen and AstraZeneca announced that the U.S. FDA approved TEZSPIRE for patients aged 12 years and older suffering from severe asthma. It has been approved for self-administration in the U.S. with a new prefilled pen. The product is also approved in the U.S., Japan, the EU, and other countries.
The increasing emphasis on precision medicine and patient-specific treatment plans is notably transforming asthma care markedly in the U.S. There is increasing interest in biomarkers and genetic profiling to effectively guide therapy decisions as healthcare shifts toward a more individualized approach. The changing scenario lets doctors spot the true sources of asthma for each patient and then choose the treatments that have the greatest effect. In addition, artificial intelligence and data analytics are being integrated into clinical practice. This integration improves diagnostic accuracy in addition to monitoring treatment. These particular clinical and technological advancements are not only enhancing therapeutic outcomes. Still, they are also creating new opportunities for pharmaceutical innovation, positioning the U.S. asthma therapeutics market for sustained, innovation-driven growth.
U.S. Asthma Therapeutics Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. asthma therapeutics market report based on drug class, device type, product, route of administration.
- Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
- Anti- inflammatory
- Bronchodilators
- Combination therapy
- Device Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Inhalers
- Nebulizers
- Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Dry Powder
- Metered Dose
- Soft Mist
- Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
- Oral
- Inhaled
- Intravenous
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR's Internal Database
- 1.3.3. Secondary Sources
- 1.3.4. Primary Research
- 1.4. Information/Data Analysis
- 1.5. Market Formulation & Visualization
- 1.6. Data Validation & Publishing
- 1.7. Model Details
- 1.7.1. Commodity flow analysis
- 1.7.2. Regional Market: CAGR Calculation
- 1.8. List of Secondary Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Asthma Therapeutics Market Variable Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market
- 3.1.2. Ancillary Market
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.3. U.S. Asthma Therapeutics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitution
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political & Legal landscape
- 3.3.2.2. Economic and Social landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Environmental landscape
- 3.3.3. Regulatory Framework
- 3.3.1. Industry Analysis - Porter's
Chapter 4. U.S. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. U.S. Asthma Therapeutics Market: Drug Class Movement Analysis
- 4.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
- 4.4. Anti-inflammatory
- 4.4.1. Anti-inflammatory Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.5. Bronchodilators
- 4.5.1. Bronchodilators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.6. Combine Therapy
- 4.6.1. Combine Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. U.S. Asthma Therapeutics Market: Device Type Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. U.S. Asthma Therapeutics Market: Device Type Movement Analysis
- 5.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Device Type, 2021 to 2033 (USD Billion)
- 5.4. Inhalers
- 5.4.1. Inhalers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.5. Nebulizers
- 5.5.1. Nebulizers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. U.S. Asthma Therapeutics Market: Product Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. U.S. Asthma Therapeutics Market by Product
- 6.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
- 6.4. Dry Powder
- 6.4.1. Dry Powder Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.5. Metered Dose
- 6.5.1. Metered Dose Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.6. Soft Mist
- 6.6.1. Soft Mist Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 7. U.S. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. U.S. Asthma Therapeutics Market: By Route of Administration Movement Analysis
- 7.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
- 7.3.1. Oral
- 7.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.3.2. Inhaled
- 7.3.2.1. Inhaled Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.3.3. intravenous
- 7.3.3.1. Intravenous Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.3.1. Oral
Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Company Market Position Analysis/ Heap Map Analysis
- 8.3. Company Profiles
- 8.3.1. Teva Pharmaceuticals Industries Ltd.
- 8.3.1.1. Participant's Overview
- 8.3.1.2. Financial Performance
- 8.3.1.3. Application Benchmarking
- 8.3.1.4. Strategic Initiatives
- 8.3.2. GSK plc
- 8.3.2.1. Participant's Overview
- 8.3.2.2. Financial Performance
- 8.3.2.3. Application Benchmarking
- 8.3.2.4. Strategic Initiatives
- 8.3.3. Merck & Co. Inc.
- 8.3.3.1. Participant's Overview
- 8.3.3.2. Financial Performance
- 8.3.3.3. Product Benchmarking
- 8.3.3.4. Strategic Initiatives
- 8.3.4. F. Hoffmann-La Roche Ltd
- 8.3.4.1. Participant's Overview
- 8.3.4.2. Financial Performance
- 8.3.4.3. Product Benchmarking
- 8.3.4.4. Strategic Initiatives
- 8.3.5. AstraZeneca
- 8.3.5.1. Participant's Overview
- 8.3.5.2. Financial Performance
- 8.3.5.3. Product Benchmarking
- 8.3.5.4. Strategic Initiatives
- 8.3.6. Boehringer Ingelheim International GmbH
- 8.3.6.1. Participant's Overview
- 8.3.6.2. Financial Performance
- 8.3.6.3. Product Benchmarking
- 8.3.6.4. Strategic Initiatives
- 8.3.7. Sanofi
- 8.3.7.1. Participant's Overview
- 8.3.7.2. Financial Performance
- 8.3.7.3. Product Benchmarking
- 8.3.7.4. Strategic Initiatives
- 8.3.8. Koninklijke Philips N.V.
- 8.3.8.1. Participant's Overview
- 8.3.8.2. Financial Performance
- 8.3.8.3. Product Benchmarking
- 8.3.8.4. Strategic Initiatives
- 8.3.9. Covis Pharma
- 8.3.9.1. Participant's Overview
- 8.3.9.2. Financial Performance
- 8.3.9.3. Product Benchmarking
- 8.3.9.4. Strategic Initiatives
- 8.3.10. Pfizer
- 8.3.10.1. Participant's Overview
- 8.3.10.2. Financial Performance
- 8.3.10.3. Product Benchmarking
- 8.3.10.4. Strategic Initiatives
- 8.3.11. Regeneron
- 8.3.11.1. Participant's Overview
- 8.3.11.2. Financial Performance
- 8.3.11.3. Product Benchmarking
- 8.3.11.4. Strategic Initiatives
- 8.3.12. Amgen
- 8.3.12.1. Participant's Overview
- 8.3.12.2. Financial Performance
- 8.3.12.3. Product Benchmarking
- 8.3.12.4. Strategic Initiatives
- 8.3.1. Teva Pharmaceuticals Industries Ltd.
List of Tables
- Table 1 List of Secondary Sources
- Table 2 U.S. Asthma Therapeutics Market, by Drug Class, 2021 - 2033 (USD Billion)
- Table 3 U.S. Asthma Therapeutics Market, by Device Type, 2021 - 2033 (USD Billion)
- Table 4 U.S. Asthma Therapeutics Market, by Product, 2021 - 2033 (USD Billion)
- Table 5 U.S. Asthma Therapeutics Market, by Route of Administration, 2021 - 2033 (USD Billion)
List of Figures
- Fig. 1 Market Segmentation
- Fig. 2 Market Research Process
- Fig. 3 Information Procurement
- Fig. 4 Primary Research Pattern
- Fig. 5 Market Research Approaches
- Fig. 6 Value Chain-Based Sizing & Forecasting
- Fig. 7 QFD Modelling for Market Share Assessment
- Fig. 8 Market Formulation & Validation
- Fig. 9 U.S. Asthma Therapeutics Market Revenue, 2021-2033 (USD Billion)
- Fig. 10 U.S. Asthma Therapeutics Market Snapshot
- Fig. 11 U.S. Asthma Therapeutics Market Driver Impact
- Fig. 12 U.S. Asthma Therapeutics Market Restraint Impact
- Fig. 13 U.S. Asthma Therapeutics Product Key Takeaways (USD Billion)
- Fig. 14 U.S. Asthma Therapeutics Market: Product Movement Analysis
- Fig. 15 Drug Class Market, 2021 - 2033 (USD Billion)
- Fig. 16 Anti-inflammatory Market, 2021 - 2033 (USD Billion)
- Fig. 17 Bronchodilators Market, 2021 - 2033 (USD Billion)
- Fig. 18 Combination Therapy Market, 2021 - 2033 (USD Billion)
- Fig. 19 U.S. Asthma Therapeutics Device Type Key Takeaways (USD Billion)
- Fig. 20 U.S. Asthma Therapeutics Market: Device Type Movement Analysis
- Fig. 21 Inhalers Market, 2021 - 2033 (USD Billion)
- Fig. 22 Nebulizers Market, 2021 - 2033 (USD Billion)
- Fig. 23 U.S. Asthma Therapeutics Market: Product Movement Analysis
- Fig. 24 Dry Powder Market, 2021 - 2033 (USD Billion)
- Fig. 25 Metered Dose Market, 2021 - 2033 (USD Billion)
- Fig. 26 Soft Mist Market, 2021 - 2033 (USD Billion)
- Fig. 27 U.S. Asthma Therapeutics Market Route of Administration Key Takeaways (USD Billion)
- Fig. 28 U.S. Asthma Therapeutics Market: Route of Administration Movement Analysis
- Fig. 29 Oral Market, 2021 - 2033 (USD Billion)
- Fig. 30 Inhaled Market, 2021 - 2033 (USD Billion)
- Fig. 31 Intravenous Market, 2021 - 2033 (USD Billion)
